3 Metro Lab Network, Wellness Testing and Rapid Molecular Kits Stocks With a Strong Future Roadmap: Dr. Lal PathLabs, Thyrocare Technologies and Molbio Diagnostics
- October 21, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Dr. Lal PathLabs, Thyrocare Technologies and Molbio Diagnostics: ROE of 14.2% to 27.9% and FY22 to FY26 revenue CAGR of 7.6% to 16.8%. Prices as of 20 Oct 2026.
Quick Answer
The three pathology and testing stocks to watch are Dr. Lal PathLabs, Thyrocare Technologies and Molbio Diagnostics. Their return on equity ranges from 14.2% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 16.8%. Thyrocare Technologies has the highest return on equity at 27.9%, while Molbio Diagnostics has the fastest revenue growth at 16.8% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.
Pathology and testing stocks let investors follow the rising habit of regular health checks and early diagnosis. Dr. Lal PathLabs, Thyrocare Technologies and Molbio Diagnostics cover a national pathology network, a wellness and preventive testing company and a maker of rapid molecular diagnostic kits.
This list covers three pathology and testing stocks with complete current figures: Dr. Lal PathLabs, Thyrocare Technologies and Molbio Diagnostics. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pathology and Testing Stocks?
Pathology and testing stocks are listed companies that run diagnostic laboratories, collection networks or manufacture the kits and instruments used in tests. Their earnings follow test volumes, revenue per patient and the reach of their collection centres.
Pathology and Testing Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Dr. Lal PathLabs | 1,843.7 | 30,949 | 56.6 | 59.6 | 20.1 | 0.08 |
| Thyrocare Technologies | 471 | 7,501 | 42.6 | 59.6 | 27.9 | 0.09 |
| Molbio Diagnostics | 1,434.8 | 16,605 | 101.2 | 59.6 | 14.2 | 0.38 |
On valuation, Dr. Lal PathLabs and Thyrocare Technologies trade at a P/E below the industry P/E, while Molbio Diagnostics trades above it, which reflects the growth the market already expects. Readers comparing pathology and testing stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Pathology and Testing Stocks Have a Strong Roadmap in India?
Pathology and testing stocks have a strong roadmap in India because awareness of preventive care is growing and doctors rely more on tests before deciding treatment.
- Preventive health. Wellness packages bring repeat customers to laboratories.
- Network reach. Collection centres and home sample pickup widen coverage in smaller cities.
- Molecular testing. Rapid and accurate tests are gaining a place in routine clinical use.
Why Dr. Lal PathLabs Features Among These Pathology and Testing Stocks
Among the pathology and testing stocks on this list, Dr. Lal PathLabs is one of India’s best-known diagnostics companies, operating a national reference laboratory with a hub-and-spoke network of labs, patient service centres and collection points.
In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%.
Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P/E of 56.6, below the industry P/E of 59.6.
Roadmap: Its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.
What to watch: Follow test volumes per patient and the balance between routine and specialised tests.
Why Thyrocare Technologies Features Among These Pathology and Testing Stocks
Among the lab testing shares on this list, Thyrocare Technologies runs a centralised, high-volume testing laboratory in Navi Mumbai and collects samples through a wide partner network of diagnostic centres, pharmacies and franchisees across India.
The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6.
Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore.
Roadmap: The centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.
What to watch: Track growth in test volume per day and the share of revenue from preventive health packages.
Why Molbio Diagnostics Features Among These Pathology and Testing Stocks
Among the three companies on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.
Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.
The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.
Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.
Dr. Lal PathLabs vs Thyrocare Technologies vs Molbio Diagnostics on Key Financials
The table below sets the three pathology and testing stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Dr. Lal PathLabs | 2,140 | 2,864 | 7.6% | 510 | 17.8% |
| Thyrocare Technologies | 618 | 846 | 8.2% | 163 | 19.2% |
| Molbio Diagnostics | 782 | 1,455 | 16.8% | 164 | 11.3% |
Thyrocare Technologies posts the highest return on equity in this group at 27.9%. Dr. Lal PathLabs has the largest FY26 revenue at Rs 2,864 crore, and Molbio Diagnostics shows the fastest revenue growth with a 16.8% compound annual rate. A useful habit with pathology and testing stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Pathology and Testing Stocks
Every theme carries risks that deserve a check before any decision. For these pathology and testing stocks, the main points are: Long-term lab testing shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Pricing pressure. Competition from other labs and online platforms can influence test prices.
- Regulatory approvals. Kits and devices depend on approvals in different markets.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pathology and testing stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pathology and Testing Stocks
Pathology and testing stocks reward investors who follow test volumes, network additions and product approvals. Dr. Lal PathLabs, Thyrocare Technologies and Molbio Diagnostics each have a clear role in the diagnostics chain. Based on the 20 October 2026 close, Dr. Lal PathLabs trades at Rs 1,843.7, Thyrocare Technologies at Rs 471 and Molbio Diagnostics at Rs 1,434.8. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pathology and testing stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pathology and testing stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pathology and testing stocks?
Ans. Pathology and testing stocks are listed companies that run diagnostic laboratories, collection networks or manufacture the kits and instruments used in tests. Their earnings follow test volumes, revenue per patient and the reach of their collection centres. This list looks at three of them, Dr. Lal PathLabs, Thyrocare Technologies and Molbio Diagnostics, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.
Which pathology and testing stocks are covered in this list?
Ans. This list covers Dr. Lal PathLabs, Thyrocare Technologies and Molbio Diagnostics. Based on the 20 October 2026 close, Dr. Lal PathLabs traded at Rs 1,843.7, Thyrocare Technologies at Rs 471 and Molbio Diagnostics at Rs 1,434.8. Their return on equity ranges from 14.2% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 16.8%.
Why do pathology and testing stocks have a strong future roadmap in India?
Ans. Pathology and testing stocks have a strong roadmap in India because awareness of preventive care is growing and doctors rely more on tests before deciding treatment. The main drivers are as follows. Preventive health. Wellness packages bring repeat customers to laboratories. Network reach. Collection centres and home sample pickup widen coverage in smaller cities. Molecular testing. Rapid and accurate tests are gaining a place in routine clinical use. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Dr. Lal PathLabs performed financially?
Ans. Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P/E of 56.6, below the industry P/E of 59.6. Looking ahead, its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.
How has Thyrocare Technologies performed financially?
Ans. Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6. Looking ahead, the centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.
How has Molbio Diagnostics performed financially?
Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What risks should investors check before buying pathology and testing stocks?
Ans. Investors should check a few risks before buying pathology and testing stocks. Pricing pressure. Competition from other labs and online platforms can influence test prices. Regulatory approvals. Kits and devices depend on approvals in different markets. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pathology and testing stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
